Apply to be as speaker or submit a poster
Your insight, experience and participation as a valued customer are incredibly important to us, and this meeting is a wonderful opportunity to connect with other customers using OncoDNA’s products and our teams.
WHY BE A SPEAKER?
Build on leadership and public speaking skills outside of your daily job function
Share expertise and success stories positioning yourself as a leader, enhancing your professional standing
Connect with peers, industry experts, and collaborators internationally who share similar challenges and interests
Expand your knowledge as presenting and inviting feedback from others can provide new perspectives, innovative ideas, and solutions that might not have been otherwise considered
Access support for travel and accommodation* to help you cover the costs of attending User Group
VERBAL PRESENTATION OR POSTER?
There is no limit to the number of submissions you make or topics you wish to present/submit posters
Topics
1. Liquid Biopsy or Tissue NGS Testing in Oncology – Competing Options or a Complimentary Strategy?
Included but not limited to presentations relating to the choice of liquid or solid kits available for laboratories to buy, what criteria was used to shortlist and then what influenced the final decision to use OncoDNA’s kits (solid or liquid or both).Descriptions of the experience of implementing OncoDNA’s kits. This could include aspects of validation, logistics, sensitivity, reporting etc. As well as the clinical applications, specific targets such as HRD and the local testing strategy is it liquid or tissue or both?
2. What are the patient centred research projects being enabled by OncoDEEP or OncoSELECT?
Included but not limited to presentations relating to the how OncoDEEP or OncoSELECT or both are enabling research projects. Describe the questions the research is aiming to answer, what patient groups/cancer types will benefit, set out the current position of the research project and the findings to date. Highlight if the project will continue and why or if there is a finite end to the project. Include where it is expected the findings will be published in the wider context. g. conferences, journals etc.
3. If Comprehensive Genomics Profiling (CGP) is enough why is Whole Exome Sequencing (WES) Interesting?
Included but not limited to presentations relating to the NGS strategy of your laboratory or country. Describe what is driving the uptake of WES beyond CGP? And the different applications in precision oncology that are best satisfied by CGP and WES. Describe the challenges and opportunities of reporting and handling data when delivering WES as compared to CGP.
4. How can insight and data be used to improve the quality of laboratory testing and used as evidence to achieve laboratory certifications?
Included but not limited to presentations that identify the different practices customers have used to evidence the quality of CGP testing enabled by OncoDEEP and OncoSELECT kits. Descriptions of quality goals, findings, improvements made (if any) as well as certifications achieved and how ongoing monitoring of quality is managed within the wider regulatory context in which the customer works. (noting that regulation will be different from country to country)
5. Why is bio-informatics central to the delivery of a genomics service?
Included but not limited to presentations that showcase the role of bioinformaticians working in smaller as well as larger laboratories and in both research and clinical diagnostic settings. Presentations should describe the regulatory requirements that need to be satisfied in the speaker’s country. The experience of using OncoDNA’s software, data storage and how integration, insights and reporting are managed. Challenges and opportunities of the bioinformaticians role should be explored given the data generated is ultimately used as a basis for interpreting genomic findings by clinicians.
6. Can automation of the ‘wetlab’ improve capacity of CGP testing and what are the other benefits of automation?
Included but not limited to addressing distinct aspects of the OncoDEEP and OncoSELECT workflow that can be automated using different sequencers and robotics to improve quality and productivity and reduce costs. Presentations might include high level automation plans, training plans and outline the benefits already realised and highlight those still being worked towards.
7. How can automation of the 'dry' lab drive efficiencies in reporting is this really a job for software or can it be combined with the human touch?
Included but not limited to addressing distinct aspects of the OncoDEEP and OncoSELECT workflow that can be automated using different sequencers and robotics to improve quality and productivity and reduce costs. Presentations might include high level automation plans, training plans and outline the benefits already realised and highlight those still being worked towards.
8. Can we debate specific Patient Samples as Case Studies for review and troubleshooting?
Please note speakers are not required for this topic as all registered delegates will be invited to submit to this live Q&A when registering for User Group
How to apply ?
Apply to speak and showcase your work
At OncoDNA, we take your privacy very seriously. We will process and use the information supplied above to contact you with the information requested and to provide you with relevant details about this event and future editions of this and other similar events/products that we think may be of interest to you. We will only ever use the information we collect or receive about you in accordance with our Privacy Policy .